Retrospective validation of the postnatal growth and retinopathy of prematurity criteria in a Chinese cohort

回顾性验证中国人群中早产儿出生后生长发育和视网膜病变诊断标准

阅读:1

Abstract

PURPOSE: To evaluate the effectiveness and applicability of the postnatal growth and retinopathy of prematurity (G-ROP) screening criteria in a Chinese neonatal cohort. METHODS: Data pertaining to the retinal screening of premature infants admitted to the neonatal intensive care unit from January 2021 through December 2021 were retrospectively analyzed. The severity of ROP was graded on the basis of the International Classification of Retinopathy of Prematurity criteria established in 2005. Treatment decisions for ROP were guided by the recommendations of the Early Treatment for Retinopathy of Prematurity Cooperative Group. The presence of six key variables that comprise the G-ROP screening criteria were carefully documented. The sensitivity and specificity of the G-ROP predictive algorithm in identifying infants with ROP requiring treatment were calculated. RESULTS: A total of 352 infants with complete records were included in this study, among whom 120 infants (34.1%) were diagnosed with ROP. Of those, 21 infants (6.0%) received treatment. By applying the 6 criteria of the G-ROP model, all infants with severe ROP were successfully identified. The sensitivity of the G-ROP model in predicting treatment-requiring ROP was 100% (CI, 0.808-1.00), and the specificity was 47.8% (CI, 0.413-0.545). By applying the G-ROP criteria, the number of infants who required ROP screening would have been reduced by 122 (34.7%), while the number of screenings (1967) would have been reduced by 537 (27.3%). CONCLUSION: The prevalence of ROP (34.1%) and treatment-requiring ROP (6.0%) were relatively high in our cohort. Application of the G-ROP prediction model can improve the sensitivity and specificity of ROP screening. All infants with treatment-requiring ROP were correctly identified. The G-ROP screening criteria seemed to be effective and appropriate for predicting ROP in infants living in Tianjin, China.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。